BACTERIAL SPECTRUM AND ANTIBIOTIC SENSITIVITY IN SPONTANEOUS BACTERIAL PERITONITIS ASSOCIATED WITH LIVER CIRRHOSIS
DOI:
https://doi.org/10.71000/wgjyfs07Keywords:
Anti-Bacterial Agents, Ascitic Fluid, Bacterial Infections, Drug Resistance, Escherichia coli, Klebsiella, Liver Cirrhosis, Microbial Sensitivity Tests, Spontaneous Bacterial Peritonitis, , StaphylococcusAbstract
Background: Spontaneous bacterial peritonitis (SBP) is a life-threatening complication of liver cirrhosis, often leading to severe morbidity and mortality. The increasing prevalence of multidrug-resistant (MDR) organisms has complicated empirical treatment protocols, particularly in regions with limited microbiological surveillance. This study aims to address the local gap in data on bacterial spectrum and antimicrobial sensitivity in cirrhotic patients with SBP.
Objective: To determine the bacterial spectrum and antibiotic sensitivity patterns in spontaneous bacterial peritonitis among patients with liver cirrhosis.
Methods: A cross-sectional study was conducted over six months at the Department of Medicine, Khyber Teaching Hospital, Peshawar. A total of 139 patients aged 30–65 years, diagnosed with SBP secondary to liver cirrhosis, were included through non-probability consecutive sampling. Ascitic fluid was analyzed for culture and sensitivity against commonly used antibiotics. Data on demographics and resistance patterns were recorded and analyzed using SPSS v27. Chi-square tests were applied post-stratification to examine associations.
Results: Escherichia coli was the most frequently isolated organism (64.0%), followed by Klebsiella spp. (40.3%) and Staphylococcus spp. (27.3%). High resistance rates were observed for ciprofloxacin and ceftriaxone among E. coli isolates (43.9% and 35.9%, respectively). Klebsiella showed equal resistance and sensitivity to ceftriaxone and piperacillin (50%), while Staphylococcus spp. remained fully sensitive to vancomycin but demonstrated significant resistance to clindamycin (52.6%) and cefazolin (57.9%).
Conclusion: The predominance of resistant E. coli and rising MDR patterns underline the need for continuous microbiological surveillance and revised empirical treatment guidelines. Local resistance profiles should guide antibiotic choices in SBP management to improve outcomes.
References
Pimentel R, Gregório C, Figueiredo P. Antibiotic prophylaxis for prevention of spontaneous bacterial peritonitis in liver cirrhosis: systematic review. Acta Gastroenterol Belg. 2021;84(2):333-42.
Arroyo V, Moreau R, Jalan R. Acute-on-chronic liver failure. N Engl J Med. 2020;382(22):2137-45.
Popoiag RE, Fierbințeanu-Braticevici C. Spontaneous bacterial peritonitis: update on diagnosis and treatment. Rom J Intern Med. 2021;59(4):345-50.
Mattos AA, Wiltgen D, Jotz RF, Dornelles CM, Fernandes MV, Mattos ÂZ. Spontaneous bacterial peritonitis and extraperitoneal infections in patients with cirrhosis. Ann Hepatol 2020;19(5):451-7.
Wong YJ, Qiu TY, Tam YC, Mohan BP, Gallegos-Orozco JF, Adler DG. Efficacy and Safety of IV albumin for non-spontaneous bacterial peritonitis infection among patients with cirrhosis: A systematic review and meta-analysis. Dig Liver Dis. 2020;52(10):1137-42.
Santoiemma PP, Dakwar O, Angarone MP. A retrospective analysis of cases of Spontaneous Bacterial Peritonitis in cirrhosis patients. Plos One. 2020;15(9): e0239470.
Ghweil AA, Bazeed SES, Al Rawy MH, Khodeary A, El-Amir MI. Fluoroquinolone-resistant strains in cirrhotic patients with spontaneous bacterial peritonitis: microbiological and molecular aspects. Eur J Gastroenterol Hepatol. 2022;34(1):64-8.
Gilani SF, Hassan F, Siddiqui FA, Gardezi SA. Frequency of symptomatic spontaneous bacterial peritonitis and associated clinical parameters in patients with liver cirrhosis: Bacterial Peritonitis in Liver Cirrhosis. Pak Armed Forces Med J. 2021;71(5):1598-602.
Bajaj JS, Rodriguez MP, Fagan A, McGeorge S, Sterling RK, Lee H, et al. Impact of bacterial infections and spontaneous bacterial peritonitis prophylaxis on phage-bacterial dynamics in cirrhosis. Hepatology. 2022;76(6):1723-34.
Marciano S, Gutierrez-Acevedo MN, Barbero S, Del CNL, Agozino M, Fernandez JL, et al. Norfloxacin prophylaxis effect on multidrug resistance in patients with cirrhosis and bacterial infections. Eur J Clin Microbiol Infect Dis. 2023;42(4):481-91.
Iqbal A, Gangwani MK, Beran A, Dahiya DS, Sohail AH, Lee-Smith W, et al. Nosocomial vs healthcare associated vs community acquired spontaneous bacterial peritonitis: Network meta-analysis. Am J Med Sci. 2023;366(4):305-13.
Collette K, Bethea A, Schadler A, Kelley JL. Outcomes in patients with spontaneous bacterial peritonitis utilizing first-line or alternative agents for secondary prophylaxis. Am J Health Syst Pharm. 2023;80(Suppl 4):S123-s9.
Yim HJ, Kim TH, Suh SJ, Yim SY, Jung YK, Seo YS, et al. Response-Guided Therapy With Cefotaxime, Ceftriaxone, or Ciprofloxacin for Spontaneous Bacterial Peritonitis: A Randomized Trial: A Validation Study of 2021 AASLD Practice Guidance for SBP. Am J Gastroenterol. 2023;118(4):654-63.
Markley JD, Bajaj JS. Rethinking Antibiotic Prophylaxis for Spontaneous Bacterial Peritonitis in Patients With Cirrhosis: First, Do No Harm. Clin Infect Dis. 2025;80(4):710-4.
Santoiemma PP, Dakwar O, Angarone MP. A retrospective analysis of cases of Spontaneous Bacterial Peritonitis in cirrhosis patients. PLoS One. 2020;15(9):e0239470.
Wong YJ, Kalki RC, Lin KW, Kumar R, Tan J, Teo EK, et al. Short- and long-term predictors of spontaneous bacterial peritonitis in Singapore. Singapore Med J. 2020;61(8):419-25.
Mattos AA, Wiltgen D, Jotz RF, Dornelles CMR, Fernandes MV, Mattos  Z. Spontaneous bacterial peritonitis and extraperitoneal infections in patients with cirrhosis. Ann Hepatol. 2020;19(5):451-7.
Popoiag RE, Fierbințeanu-Braticevici C. Spontaneous bacterial peritonitis: update on diagnosis and treatment. Rom J Intern Med. 2021;59(4):345-50.
Caraceni P, Vargas V, Solà E, Alessandria C, de Wit K, Trebicka J, et al. The Use of Rifaximin in Patients With Cirrhosis. Hepatology. 2021;74(3):1660-73.
Helil AS, Haile SA, Birhanu Y, Desalegn H, Desalegn DM, Geremew RA, et al. Bacterial profile, drug resistance pattern, clinical and laboratory predictors of ascites infection in cirrhosis patients. BMC Infect Dis. 2024;24(1):528.
Zhang X, Li XX, Song JW, Zhang XC, Zhen C, Bi JF, et al. Clinical features, microbial spectrum, and antibiotic susceptibility patterns of spontaneous bacterial peritonitis in cirrhotic patients. Dig Liver Dis. 2023;55(11):1554-61.
Avadhanam M, Kulkarni AV. Conventional Antibiotics for Spontaneous Bacterial Peritonitis: Are They Still Effective? Am J Gastroenterol. 2023;118(4):613-4.
Mücke MM, Mücke VT, Graf C, Schwarzkopf KM, Ferstl PG, Fernandez J, et al. Efficacy of Norfloxacin Prophylaxis to Prevent Spontaneous Bacterial Peritonitis: A Systematic Review and Meta-Analysis. Clin Transl Gastroenterol. 2020;11(8):e00223.
Silvey S, Patel NR, Tsai SY, Nadeem M, Sterling RK, Markley JD, et al. Higher Rate of Spontaneous Bacterial Peritonitis Recurrence With Secondary Spontaneous Bacterial Peritonitis Prophylaxis Compared With No Prophylaxis in 2 National Cirrhosis Cohorts. Am J Gastroenterol. 2025;120(5):1066-75.
Pimentel R, Leitão J, Gregório C, Santos L, Carvalho A, Figueiredo P. Spontaneous bacterial peritonitis in cirrhotic patients: a shift in the microbial pattern? A retrospective analysis. J Gastroenterol. 2022;29(4):256-66.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Sohrab Khan, Inam Ullah Khan, Zahid Ullah, Essa Hassan, Saif Ullah, Muhammad Aitizaz, Muhammad Aman Khan (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
